Pazopanib

Abstract

Pazopanib (GW-786034) is a second-generation multi-targeted tyrosine kinase inhibitor, which blocks VEGFR-1, VEGFR-2 and VEGFR-3, PDGFR-α, PDGFR-β and c-kit. Based on data from a randomized, double-blind multicenter phase III study (n=435) showing that it significantly increased progression-free survival relative to placebo (9.2 months vs 4.2 months; p<0.001), the United States Food and Drug Administration (FDA) approved pazopanib as the sixth drug to be approved for renal cell cancer on October 19, 2009. Ongoing trials are further evaluating pazopanib in various other malignancies.